Bupivacaine Effectiveness and Safety in SABER Trial (BESST).

Trial Profile

Bupivacaine Effectiveness and Safety in SABER Trial (BESST).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms BESST
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 16 May 2014 According to the DURECT corporation media release, cardiac safety data from this trial were presented at the International Anesthetic Research Society (IARS) Annual Meeting.
    • 05 Jan 2012 Primary endpoint 'Additional-treatment-required---rescue-medication' has not been met.
    • 05 Jan 2012 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top